Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact - PubMed (original) (raw)
Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact
A P S Hungin et al. Aliment Pharmacol Ther. 2005.
Abstract
Background: The impact of irritable bowel syndrome, a gastrointestinal motility disorder, is underestimated and poorly quantified, as clinicians may see only a minority of sufferers.
Aim: To determine the prevalence, symptom patterns and impact of irritable bowel syndrome in the US.
Methods: This two-phase community survey used quota sampling and random-digit telephone dialing (screening interview) to identify individuals with medically diagnosed irritable bowel syndrome or individuals not formally diagnosed, but fulfilling irritable bowel syndrome diagnostic criteria (Manning, Rome I or II). Information on irritable bowel syndrome symptoms, general health status, lifestyle and impact of symptoms on individuals' lives was collected using in-depth follow-up interviews. Data were also collected for healthy controls identified in the screening interviews.
Results: The total prevalence of irritable bowel syndrome in 5009 screening interviews was 14.1% (medically diagnosed: 3.3%; undiagnosed, but meeting irritable bowel syndrome criteria: 10.8%). Abdominal pain/discomfort was the most common symptom prompting consultation. Most sufferers (74% medically diagnosed; 63% undiagnosed) reported alternating constipation and diarrhoea. Previously diagnosed gastrointestinal disorders occurred more often in sufferers than non-sufferers. Irritable bowel syndrome sufferers had more days off work (6.4 vs. 3.0) and days in bed, and reduced activities to a greater extent than non-sufferers.
Conclusions: Most (76.6%) irritable bowel syndrome sufferers in the US are undiagnosed. Irritable bowel syndrome has a substantial impact on sufferers' well-being and health, with considerable socioeconomic consequences.
Similar articles
- Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population.
Hillilä MT, Färkkilä MA. Hillilä MT, et al. Aliment Pharmacol Ther. 2004 Aug 1;20(3):339-45. doi: 10.1111/j.1365-2036.2004.02034.x. Aliment Pharmacol Ther. 2004. PMID: 15274671 - Prevalence of irritable bowel syndrome: a community survey.
Wilson S, Roberts L, Roalfe A, Bridge P, Singh S. Wilson S, et al. Br J Gen Pract. 2004 Jul;54(504):495-502. Br J Gen Pract. 2004. PMID: 15239910 Free PMC article. - Prevalence, bowel habit subtypes and medical care-seeking behaviour of patients with irritable bowel syndrome in Northern Greece.
Katsinelos P, Lazaraki G, Kountouras J, Paroutoglou G, Oikonomidou I, Mimidis K, Koutras C, Gelas G, Tziomalos K, Zavos C, Pilpilidis I, Chatzimavroudis G. Katsinelos P, et al. Eur J Gastroenterol Hepatol. 2009 Feb;21(2):183-9. doi: 10.1097/MEG.0b013e328312eb97. Eur J Gastroenterol Hepatol. 2009. PMID: 19212207 - Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study.
Brun-Strang C, Dapoigny M, Lafuma A, Wainsten JP, Fagnani F. Brun-Strang C, et al. Eur J Gastroenterol Hepatol. 2007 Dec;19(12):1097-103. doi: 10.1097/MEG.0b013e3282f1621b. Eur J Gastroenterol Hepatol. 2007. PMID: 17998835 Review. - Irritable bowel syndrome: the burden and unmet needs in Europe.
Quigley EM, Bytzer P, Jones R, Mearin F. Quigley EM, et al. Dig Liver Dis. 2006 Oct;38(10):717-23. doi: 10.1016/j.dld.2006.05.009. Epub 2006 Jun 27. Dig Liver Dis. 2006. PMID: 16807154 Review.
Cited by
- High Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAP) Consumption Among Endurance Athletes and Relationship to Gastrointestinal Symptoms.
Killian LA, Muir JG, Barrett JS, Burd NA, Lee SY. Killian LA, et al. Front Nutr. 2021 Apr 20;8:637160. doi: 10.3389/fnut.2021.637160. eCollection 2021. Front Nutr. 2021. PMID: 33959628 Free PMC article. - Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic.
Charbonneau D, Gibb RD, Quigley EM. Charbonneau D, et al. Gut Microbes. 2013 May-Jun;4(3):201-11. doi: 10.4161/gmic.24196. Epub 2013 Apr 2. Gut Microbes. 2013. PMID: 23549409 Free PMC article. Clinical Trial. - Pattern of irritable bowel syndrome and its impact on quality of life in primary health care center attendees, Suez governorate, Egypt.
Abdulmajeed A, Rabab MA, Sliem HA, Hebatallah NE. Abdulmajeed A, et al. Pan Afr Med J. 2011;9:5. doi: 10.4314/pamj.v9i1.71177. Epub 2011 May 18. Pan Afr Med J. 2011. PMID: 22145053 Free PMC article. - Utility of Analgesic and Anxiolytic Medication Dose during Colonoscopy in Identifying Patients with Irritable Bowel Syndrome.
Lule E, Iddings E, Manandhar L, Grandhi B, Clements J. Lule E, et al. ISRN Gastroenterol. 2012;2012:969015. doi: 10.5402/2012/969015. Epub 2012 Jan 4. ISRN Gastroenterol. 2012. PMID: 22272379 Free PMC article. - Sex differences in zymosan-induced behavioral visceral hypersensitivity and colorectal afferent sensitization.
Guo T, Liu J, Chen L, Bian Z, Zheng G, Feng B. Guo T, et al. Am J Physiol Gastrointest Liver Physiol. 2024 Feb 1;326(2):G133-G146. doi: 10.1152/ajpgi.00081.2023. Epub 2023 Dec 5. Am J Physiol Gastrointest Liver Physiol. 2024. PMID: 38050686
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources